{
  "ticker": "LLY",
  "target_date": "2025-01-15",
  "actual_date": "2025-01-15",
  "collected_at": "2025-12-08T11:16:49.648038",
  "price": {
    "open": 743.45,
    "high": 749.01,
    "low": 729.83,
    "close": 741.21142578125,
    "volume": 5736900,
    "change_1d_pct": 0.25,
    "change_7d_pct": -4.51,
    "change_30d_pct": -6.11
  },
  "technicals": {
    "rsi_14": 32.65,
    "sma_20": 771.12,
    "sma_50": 779.35,
    "macd": -7.632,
    "macd_signal": -6.081,
    "macd_histogram": -1.55,
    "bb_upper": 802.95,
    "bb_lower": 739.29,
    "price_vs_sma20_pct": -3.88,
    "price_vs_sma50_pct": -4.89,
    "volume_ratio": 1.52
  },
  "fundamentals": {
    "market_cap": 890302627840,
    "pe_ratio": 48.659237,
    "forward_pe": 43.82767,
    "price_to_book": 37.39213,
    "price_to_sales": 14.983266,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.69,
    "pct_from_52w_low": 59.21
  },
  "macro": {
    "spy": {
      "price": 587.63,
      "change_1d_pct": 1.82,
      "change_7d_pct": -0.43
    },
    "vix": {
      "level": 16.12,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.65
    },
    "dollar_index": {
      "level": 109.09
    },
    "gold": {
      "price": 2712.5
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Correction to Eli Lilly Receives Approval for Crohn's Treatment Article",
      "source": "Finnhub",
      "datetime": 1736964908,
      "summary": "Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. Eli Lilly Receives FDA Approval for Crohn's Disease Treatment, at 4:25 p.m. ET, and in a subsequent update, incorrectly...",
      "url": "https://finnhub.io/api/news?id=db3f404ee19151468db504ed8d6b6534dc9fc68388efa514a50e4c5cbb6bafa0"
    },
    {
      "headline": "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment",
      "source": "Finnhub",
      "datetime": 1736959273,
      "summary": "By Connor Hart Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes...",
      "url": "https://finnhub.io/api/news?id=b5f9b41886b90dd97499137684ecd742358e71b134f7efc52517ebc4c2b41a11"
    },
    {
      "headline": "Eli Lilly Receives FDA Approval for Crohn\u2019s Disease Treatment",
      "source": "DowJones",
      "datetime": 1736958660,
      "summary": "Eli Lilly Receives FDA Approval for Crohn\u2019s Disease Treatment",
      "url": "https://finnhub.io/api/news?id=a89a9cffdd76b3240a336e0939f3000a5430407e0ceca0e06124b3633eedf950"
    },
    {
      "headline": "After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.",
      "source": "DowJones",
      "datetime": 1736958202,
      "summary": "After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.",
      "url": "https://finnhub.io/api/news?id=efc91610006206ab31570735b136449d36c93bb7c5af65fa8c759c6a8560ca9f"
    },
    {
      "headline": "FDA approves Lilly's Omvoh\u00ae (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease",
      "source": "Finnhub",
      "datetime": 1736957285,
      "summary": "In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one yearAmong those who achieved clinical...",
      "url": "https://finnhub.io/api/news?id=5ccebabf9be0372ab0eb78bfea04ff7b2fa993d9e6f6219120ed7f8232175348"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "8-K",
      "date": "2025-01-14",
      "description": "lly-20250114.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000005/lly-20250114.htm"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}